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Title: Novel avenues for Clostridium difficile infection drug discovery 
Abstract 
Introduction: Clostridium difficile is the etiologic agent of nosocomial and community-acquired 
diarrhoea associated with exposure to antibiotics that disrupt the normal colonic flora. As 
antibacterials currently used for primary C. difficile infections favour recurrences, new agents able 
to neutralize the bacterium without affecting the gut microbiota are badly needed. 
Areas covered: The most promising strategies aimed at developing therapies with minimal or no 
effect on the intestinal flora, such as new narrow-spectrum antibiotics and antimicrobial peptides, 
bacteriophages and phage lysins, virulence-targeting factors such as riboswitch ligands and quorum 
sensing-interfering factors, bacteriotherapy based on probiotics and faecal transplant, and toxin-
targeting molecules. 
Expert opinion: Beyond the development of new antibiotics, virulence-targeting factors or phage 
cocktails seem promising strategies, which could replace antibiotics avoiding the emergence of 
resistant strains and the onset of C. difficile infection (CDI). Until broad-spectrum antimicrobials 
will be in use, C. difficile-specific lytic phages could help to prevent CDI by eliminating C. difficile 
in patients and in the hospital staff, and for the prevention and treatment of recurrences. Phage 
therapy is not currently available in Western countries, but, in our opinion, it should have a new 
chance. Faecal therapy is emerging as a very effective and readily available treatment for 
recurrences. The shift is from a standardized, drug-based antibacterial therapy toward the 
forthcoming less expensive and non-patentable procedures of a more personalized medicine. This 
will imply profound changes affecting both patient-physician interactions and the current profit-
oriented approach to the pharmacologic therapy of infections.  
 
Keywords: antibiotics; antimicrobial peptides; Clostridium difficile; faecal therapy; phage therapy; 
probiotics; toxins; virulence factors.  
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1. Introduction 
Clostridium difficile is a Gram-positive anaerobe spore-forming bacillus, which in the late 1970s 
was identified as the causative agent of antibiotic-associated pseudomembranous colitis [1]. For a 
thorough retrospective review on C. difficile infection (CDI), the reader is referred to [2,3]. The 
spores of the bacterium are transmitted via the faecal-oral route, and since 2001 CDI is emerging as 
the leading cause of hospital-acquired diarrhoea in adults, with an incidence and severity increase 
that makes C. difficile one of the most important healthcare-associated pathogens worldwide [4,5]. 
Furthermore, CDI onset in non-hospitalized patients is a growing problem, as community-acquired 
cases represent, depending on CDI case definition, 20-50% of all CDI cases identified in the USA, 
Canada, and Europe [6].  
The onset of the disease is associated with the use of antibiotics that disrupt the equilibrium 
of the intestinal microflora. The antibiotics most frequently implicated prior to 2000 were 
clindamycin and cephalosporins, especially cefotaxime and ceftazidime. More recently, 
fluoroquinolones emerged as major inducing agents [7]. Advanced age (over 65), gastrointestinal 
surgery, permanence in acute or chronic care facilities, and temporary or permanent 
immunodeficiency of any origin, are significant risk factors.  
The increase in CDI frequency and severity is attributed to the spread in Western countries 
of the hyper-virulent North American Pulsed field type 1, restriction endonuclease analysis type BI, 
and polymerase chain reaction ribotype 027, known as the NAP1/BI/027 strain. Unlike historic 
strains, the new one is resistant to newer fluoroquinolones, such as gatifloxacin and moxifloxacin. It 
is also highly toxigenic in vitro, which accounts for the greater severity of symptoms and the high 
rates of recurrence and mortality [8]. Gene regulation studies suggest that fluoroquinolones could 
favour C. difficile 027 infections not only by disrupting the barrier microbiota, but also by 
enhancing the expression of C. difficile virulence and colonisation factors [9]. Another hypervirulent 
strain, ribotype 078, was identified in the Netherlands as the predominant strain in pigs and calves. 
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In humans, it causes a disease with a grade of severity similar to that of the 027 ribotype, but it 
affects a younger population and is more frequently community-associated [10].  
The severity of CDI may range from mild self-limiting diarrhoea to more serious and 
sometimes fatal conditions such as pseudo-membranous colitis, sepsis syndrome, toxic megacolon, 
and colonic perforation [11]. The acute disease is initially manifested by nausea, vomiting, diarrhoea 
with mucus and rarely blood in the stool (5% of cases), abdominal pain, fever, leukocytosis, and 
dehydration. These symptoms are due to the production of two toxins, referred to as TcdA and 
TcdB, transcribed from a pathogenicity locus that comprises five genes: tcdA and tcdB for toxins, 
and tcdR, tcdE, tcdC, three regulatory genes that encode TcdR, a bacterial transcription initiation 
factor (σ factor), TcdE, a putative holin, and TcdC, an anti-σ factor, respectively. The expression of 
tcdA and tcdB is positively regulated by TcdR and negatively regulated by TcdC [12]. In the NAP-
1/027 hypervirulent strains, tcdC deletion mutations are associated with an increase by more than a 
factor of 10 in A and B toxin production [13]. Some strains also produce a third toxin, whose role in 
CDI pathogenesis is unclear. It is known as binary toxin and is encoded by the ctdA and ctdB genes, 
which are located outside the pathogenicity locus. For a thorough and up to date review on the role 
of A and B toxins in CDI, see [14].  
Major therapeutic challenges concerning the chronic form are: i) the treatment of toxin-
induced colonic inflammation and of ileus, which prolongs the permanence of the pathogen and 
prevents the diffusion of orally-administered antimicrobials to the infected areas; ii) the prevention 
of recurrences, which occur in ~20%-40% of patients, the percentage varying with the infecting 
strain and the drug used. Since 1983, standard therapy relies on metronidazole (Fig. 1, 1) for the 
treatment of mild to moderate CDI, and, in the last decade, on vancomycin (Fig. 1, 2) for severe 
CDI. Unfortunately, these drugs also behave as recurrence-inducing factors, as suggested by the 
finding that 40% of recurrences are reinfections caused by different strains, and as demonstrated by 
experiments in hamster infection models [15]. The C. difficile resistance to antimicrobials varies 
widely between countries. Whereas most isolates are susceptible to metronidazole and vancomycin, 
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decreased sensitivity against metronidazole has been reported in Spain and UK, and sporadic cases 
of resistance to vancomycin are being reported in Poland, Spain and Scotland [16]. Bacitracin, 
teicoplanin, and fusidic acid were evaluated for CDI treatment, but they did not show any advantage 
over metronidazole and vancomycin [17]. In 2011 fidaxomicin (Fig. 1, 3), a new macrocyclic RNA 
polymerase inhibitor produced by Actinoplanes deccanensis, was approved by the US Food and 
Drug Administration (FDA) for CDI treatment[18]. Fidaxomicin is the last of the four novel 
antibiotics that entered the market in the last decade (the other three being linezolid, daptomycin 
and retapamulin). It is administered by the oral route and its efficacy is comparable to that of 
vancomycin but, thanks to its narrower spectrum of activity, it has a less disruptive effect on the 
intestinal flora, resulting in greater tolerability and in lower risk of recurrences, especially among 
non-NAP1-associated infections. The major disadvantage of fidaxomicin is the cost, as the current 
price of a treatment course exceeds 2500 US dollars [18].  
Short-term alternative options for CDI treatment could take advantage of some molecules 
recently developed for other pathologies. Uncontrolled trials and single-case reports suggest that 
molecules such as the anti-protozoal agent nitazoxanide, as well as teicoplanin, rifaximin, approved 
in the US for traveller’s diarrhoea, and the broad-spectrum antibiotic tigecycline, none of which 
approved for CDI, might be useful for the treatment of recurrences or severe complicated cases [19].  
This review deals with the most promising strategies aimed at the identification and 
development of new therapies, and is focused on the following topics: i) new antibiotics; ii) 
structurally and functionally different agents, including antimicrobial peptides, riboswitch ligands, 
quorum sensing-interfering factors, bacteriophages, phage lysins, and prebiotics; iii) toxin-targeting 
molecules; iv) bacteriotherapy, in the form of probiotics or faecal transplant.  
 
2. New antibiotics 
The search for new antibiotics to be used against C. difficile poses specific problems, linked to the 
bacterium and its ecosystem: i) the constitutive resistance to a number of in-use antibiotics requires 
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the identification of new molecular scaffolds to avoid cross-resistance; ii) the new antibiotic should 
have a very narrow spectrum of activity, so to avoid any further disruption of the protective 
intestinal microbiota, an event that leaves the patient more susceptible to recurrences; iii) it would 
be desirable to obtain drugs active against multiple targets, because single target drugs are likely to 
elicit rapid emergence of resistance; iv) to be approved and have a market, new drugs should at least 
not be inferior to, and possibly be less expensive than, fidaxomicin, which for now is a pretty good 
choice. We shall now outline a series of molecules that, at least in part, meet these conditions and 
are under advanced development.  
CB-183,315 (Fig. 2, 4), by Cubist Pharmaceuticals Inc. (Lexington, MA, USA), is an orally 
available lipopeptide antibiotic structurally related to daptomycin (Fig. 2, 5), with which it shares 
the peptide sequence and the ability to alter the membrane potential of target cells [20]. CB-183,315 
showed good activity against different C. difficile isolates, including those with elevated MICs 
against metronidazole, moxifloxacin, and vancomycin. The lack of activity of CB-183,315 against 
Enterobacteriaceae and species of the Bacteroides fragilis group suggests a low impact, similar to 
that of fidaxomicin, on the gut normal flora [21]. These properties should result in high cure and low 
recurrence rates. CB-183,315, which recently completed phase II clinical trials and is currently in 
phase III, may therefore be considered a suitable candidate for further clinical development [20].  
The unrelated compound ramoplanin (Fig. 2, 6), which targets lipid-II, has been in clinical 
development for many years and in 2009 it was acquired by Nanotherapeutics Inc. (Alachua, FL, 
USA). Ramoplanin is an oral lipoglycodepsipeptide with good activity against Gram-positive, but 
not Gram-negative, organisms, and was originally developed for the prevention of bloodstream 
infections by vancomycin-resistant Enterococci. The drug is not absorbed from the gastrointestinal 
tract of patients suffering from pseudomembranous colitis, and its in vitro activity is comparable to 
that of vancomycin [22]. In a CDI hamster model both vancomycin and ramoplanin reduced the 
number of C. difficile and led to symptom resolution. In an in vitro gut model originally developed 
by Mcfarlane et al. [23], ramoplanin, but not vancomycin, achieved almost complete elimination of 
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C. difficile spores [22]. In principle, this sporicidal property should diminish the number of relapses 
caused by the retention of viable spores in the gut, and limit the spreading of infection. Ramoplanin 
was evaluated in a phase II trial for the treatment of CDI, and was approved by the US Food and 
Drug Administration for a Special Protocol Assessment non-inferiority trial against vancomycin for 
phase III [24,25]. 
Oritavancin (Fig. 3, 7) is an oral semisynthetic lipoglycopeptide originally synthesized by 
Eli Lilly in an effort to identify vancomycin analogs with better pharmacodynamic characteristics 
and able to overcome vancomycin resistance. After several changes of ownership, oritavancin was 
acquired by The Medicines Company (Parsippany, NJ, USA), which is currently developing it in 
phase III trials as a 1200-mg single dose for the treatment of acute bacterial skin and skin structure 
infections, including those due to methicillin-resistant Staphylococcus aureus [26]. The molecule 
demonstrated good activity against C. difficile in an in vitro human gut model [27]. It also has a long 
half-life (150 to 300 h, compared with a half-life of 6 h for vancomycin) [28] and a low propensity 
to select resistant strains, probably due to its threefold mechanism of action, which includes 
transglycosilation and transpeptidation inhibition and cell membrane disruption [26].  
Replidyne, Inc. (Louisville, CO. USA) began the development of REP3123 (Fig. 3, 8), a 
novel diaryldiamine that inhibits the C. difficile methionyl-tRNA synthetase and has a narrow 
spectrum of antibacterial activity, being inactive against many other anaerobes that comprise the 
normal intestinal flora, such as Clostridium ramosum, bifidobacteria, lactobacilli and Gram-
negative anaerobes [29,30]. The molecule has bacteriostatic activity, and compared favourably with 
vancomycin in inhibiting C. difficile growth and toxin and spore production in vitro. In a CDI 
hamster model, REP3123 was superior to vancomycin in the overall animal survival. In the words 
of Ochsner et al. [31] REP3123 could be a promising candidate for CDI treatment However, since 
the completion of preclinical studies in 2009, no clinical trials are reported.  
A new prototype drug candidate, MBX-500 (Fig. 3, 9), is currently developed by 
Microbiotix Inc. and GLSynthesis Inc. (both at Worcester, MA, USA). MBX-500 is a hybrid 
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molecule formed by an anilinouracil inhibitor of the Gram-positive replication-specific DNA 
polymerase (pol IIIC), linked to a fluoroquinolone DNA gyrase/DNA topoisomerase IV inhibitor 
[32]. It was developed to treat antibiotic-resistant Gram-positive aerobic pathogens, but recently it 
was shown to be active both in vitro and in vivo against a panel of antibiotic-sensitive and -resistant 
C. difficile isolates, including the NAP1/027 ribotype [33]. The strengths of MBX-500 are: oral 
administration, local activity with no systemic absorption, narrow antibacterial spectrum, and low 
probability to select resistant strains, thanks to its ability to target three different bacterial enzymes 
involved in DNA replication. These characteristics make the molecule an excellent candidate for 
further development [33]. 
Novartis (NIBR, Cambridge, MA, USA) is currently developing a molecule named LFF571, 
obtained by optimization of a macrocyclic natural product, a thiopeptide-based secondary 
metabolite produced by the rare actinomycete Planobispora rosea [34]. The drug, which can be 
administered by the oral route, is entering a phase II trial to assess the safety and efficacy of 
multiple daily dosing in patients with moderate C. difficile infections [35].  
By the end of December 2012 Actelion Pharmaceuticals Ltd. (Allschwil, Switzerland) 
announced the decision to move forward to phase III clinical development of cadazolid (ACT-
179811) in patients suffering from C. difficile diarrhoea [36]. Cadazolid is a new chimeric antibiotic 
with structural elements of the oxazolidinone as well as the quinolone class of antibiotics. It inhibits 
C. difficile protein synthesis leading to strong suppression of toxin production and spore formation. 
In preclinical studies, cadazolid showed high in vitro activity against C. difficile clinical isolates 
coupled with a low impact on bacteria of the normal gut microflora. Other strong points of 
cadazolid are its low propensity for resistance development and its negligible absorption, resulting 
in high gut lumen concentrations and low systemic exposure, even in severe CDI cases, when the 
gut wall is severely damaged and permeability to drugs is potentially increased [37]. 
 
3. Antimicrobial peptides (AMPs) 
 9
Since the 1990s, AMP development was considered a promising mining field for new drugs against 
multiresistant pathogens [38]. Antimicrobials of peptidic nature fall into two classes: the gene-
encoded, ribosomally synthesized peptides, and the non-ribosomally synthesized peptide antibiotics, 
typically produced by bacteria and fungi. The latter are assembled by multi-enzyme complexes, 
contain d-amino acids and other non-proteinogenic amino acids, and often have a cyclic or 
branched structure [39]. The ribosomally synthesized antimicrobials can be subdivided into two 
further classes depending on their source: strictly speaking, the term “antimicrobial peptides” refers 
to peptides of eukaryotic origin, whereas peptides and proteins produced by bacteria are referred to 
as bacteriocins. Based on their electrical charge, AMPs can be divided into anionic and cationic 
peptides (AAMPs and CAMPs, respectively). AAMPs, found in vertebrates, invertebrates and 
plants, are active against bacteria, fungi, viruses, nematodes and insects. Whereas AAMPs have so 
far received little attention in the literature (for an outline of AAMP characteristics, see the 
exhaustive review by Harris et al. [40]), CAMPs are included among the most promising candidates 
for the development of new biomedical alternatives [41]. Prokaryotic bacteriocins, which include the 
already in use colistin (polymyxin E), daptomycin, and lipopeptides, are attracting renewed interest 
both as alternatives to conventional drugs and because they are a feature of probiotic bacteria 
[42,43]. 
 
3.1 Lantibiotics (class I bacteriocins) 
Lantibiotics are small (19-39 amino acids), heat-stabile, post-translationally modified peptides 
containing the non-proteinogenic amino acids lanthionine or methyl-lanthionine. They are active 
against Gram-positive bacteria and some of them, such as nisin and lacticin, are widely used as 
antibacterial agents by the food and agricultural industry in more than 50 countries [44,45]. Many 
lantibiotics are extremely potent antibacterial agents with minimum inhibitory concentrations (MIC) 
in the nanomolar range [46]. Their mode of action involves the binding to lipid II at a site that is 
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different from the one affected by vancomycin and related glycopeptides, so they are also active 
against multi-drug resistant strains.  
The experimental drug NVB302, which together with mersacidine and cinnamycin belongs 
to the family of globular type-B lantibiotics, is being developed by Novacta Biosystems Ltd. 
(Welwyn Garden City, Hertfordshire, UK) with support from a Strategic Award from the Wellcome 
Trust. NVB302 is a semi-synthetic, chemically modified peptide derived from the parent antibiotic 
desoxyactagardine B, produced by the actinomycete Actinoplanes liguriae [47]. In an in vitro human 
gut model, NVB302 was not inferior to vancomycin in the treatment of CDI, but was associated 
with faster resolution of the B. fragilis group [48]. Recently, NVB302 successfully completed a 
phase I tolerance clinical trial, and it is scheduled for phase II and III clinical trials in CDI patients 
[49].  
Another interesting lantibiotic is mutacin 1140, a 22-amino acid peptide produced by 
Streptococcus mutans [50]. It is active against a wide range of Gram-positive bacteria, including C. 
difficile, with a mechanism that involves lipid II binding and sequestration [51]. A synthetic version, 
named mutacin 1140-S, developed by Oragenics Inc. (Tampa, FL, USA), is concluding preclinical 
testing. The molecule possesses a set of good pharmaceutical properties, such as chemical stability, 
negligible toxicity, and in vivo efficacy. On the basis of these findings, to which may be added the 
lack of resistant and genetically stable spontaneous mutants, mutacin 1140-S is scheduled for 
further development and phase II and III trials [52]. 
 
3.2 Two component bacteriocins (class IIb bacteriocins) 
Bacteriocin production is considered an important trait of probiotic organisms, and the efficacy of 
bacteriocin-producing strains of Lactobacillus salivarius in the reduction of intestinal infection by 
Listeria monocytogenes was unequivocally demonstrated in vivo [53]. A two-component lantibiotic 
called lacticin 3147, produced by a strain of Lactococcus lactis originally isolated from an Irish 
kefir grain [54], is active against C. difficile at low concentrations and physiological pH [55]. 
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However, it was subsequently observed that this bacteriocin has a massive impact, comparable to 
that of metronidazole and vancomycin, on the normal gut microbiota [56].  
In an effort to isolate narrow-spectrum bacteriocins effective against C. difficile but with a 
low impact on gut microbiota, Rea et al. screened more than 30,000 bacterial isolates from faecal 
samples [57]. The screening resulted in the identification of thuricin CD, a new two-component 
bacteriocin produced by Bacillus thuringiensis, which is a spore-forming Gram-positive organism 
used in agriculture to control insects harmful to crops. The two peptides that make up the molecule 
of thuricin CD (Trn-α and Trn-β) are active at concentrations of 5 µM and 0.5 µM, respectively. 
However, the activity is greatly enhanced when both peptides are present, reducing the MIC50 to 
nanomolar values with an optimal 1:2 ratio of Trn-α:Trn-β. Following a series of in vitro tests 
against a broad range of Gram-positive and Gram-negative bacteria, thuricin CD showed a spectrum 
of activity mainly restricted to a set of spore-forming Gram-positive bacteria including clinically 
significant and hypervirulent C. difficile isolates, with a negligible impact on the intestinal flora [56]. 
In an ex vivo model of the distal colon, thuricin CD compared very favourably with metronidazole, 
suggesting that it could be used in CDI therapy, provided that its biological activity is protected 
from proteolytic enzymes by encapsulation technologies to ensure the delivery of biologically 
active peptides to the colon [58]. The posttranslational modifications found in thuricin CD are 
unusual, and had not previously been associated with two-peptide bacteriocins. Trn-α and Trn-β 
both possess three intrapeptide sulphur to α-carbon bridges, an unusual trait resulting from post-
translational modifications performed by the TrnC and TrnD enzymes. These enzymes belong to the 
family of radical S’-adenosylmethionine (SAM) proteins, that catalyze unusual reactions involved 
in the biosynthesis and degradation pathways of DNA precursors, vitamins, cofactors and 
antibiotics [59]. Radical SAM protein-encoding genes are rare in bacteriocin-associated clusters but 
an in silico screen for novel thuricin CD-like gene clusters using the TrnC and TrnD radical SAM 
proteins as driver sequences allowed the identification of fifteen novel thuricin CD-like gene 
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clusters [60]. This instance shows the possibilities offered by genomic mining of known operons to 
open new horizons in the field of antimicrobial discovery.  
 
3.3 Host defence peptides (HDPs) 
HDPs are components of the host innate defence against pathogens. In mammals, they also 
participate in the modulation of the specific immune response. Among HDPs, the cationic, cysteine-
rich defensins constitute one of the most thoroughly investigated families, which includes many 
structurally related peptides found in vertebrates, fungi, plants and insects [60]. In humans, defensins 
contribute to maintain a stable commensal microbiota in the intestinal tract, preventing bacterial 
overgrowth. It is hypothesized that reduced defensin concentrations compromise host defence and 
predispose to inflammatory bowel disease [61]. Many mammalian HDPs modulate cytokine 
production and lower the local inflammatory response by sequestering bacterial lipopolysaccharides 
and lipoteichoic acids, so preventing their interaction with the Toll-like receptors [62].  
Human α-defensins can affect CDI severity by inhibiting C. difficile toxin B activity. The 
human α-defensins HNP-1, HNP-3, and HD-5 prevent the cytotoxic effects of toxin B in the 
intestinal epithelial cells and in a large array of other cell types [63]. It has been estimated that HD-
5, a defensin produced by Paneth cells, might be present in the lumen of small intestine at 
concentrations of 50-250 µg/mL, which would be sufficient to block the action of toxin B. Whether 
the low virulence of C difficile in the small intestine is related to the occurrence of toxin-
inactivating peptides remains to be clarified [63]. However, for now the development of human 
defensins for therapeutic use has been hindered by production difficulties, cellular toxicity, and 
concerns about the possible dysregulation of the gut cytokine milieu [64,65].  
A cDNA encoding coprisin, a defensin-like peptide, was identified in a bacteria-immunized 
dung beetle, Copris tripartitus, by using differential dot blot hybridization [66]. The core structure 
of invertebrate defensins is composed of an α-helical domain linked to a two-stranded antiparallel 
β-sheet with three or four disulphide bonds forming the so-called cysteine-stabilized α-helix β-sheet 
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motif. Defensin bacterial killing is mediated by membrane disorganization, which takes seconds to 
minutes, and/or by the binding to intracellular targets, which takes more time (3-5 hours). Neither of 
the two mechanisms is receptor-based, consistent with the finding that D-peptides are generally as 
active as L-peptides [67]. The analysis of the natural coprisin peptide, consisting of 43 amino acids, 
showed that the antibacterial activity resides in the α-helical domain of the molecule. Since D-
enantiomeric peptides are known to be extremely resistant to proteases, both D- and L-enantiomeric 
analogues based on this domain were synthesized [68]. In vitro antibacterial assays demonstrated 
that both enantiomers were almost as active as vancomycin against C. difficile, but, unlike 
vancomycin, they did not inhibit Lactobacillus and Bifidobacterium species. The activity of 
coprisin consists in a selective alteration of the plasma membrane of C. difficile but not of 
Lactobacillus and Bifidobacterium cells, resulting in a significant inhibition of C. difficile growth in 
vitro.  
These results, together with the observation that in a mouse CDI model the oral 
administration of a coprisin analogue improved survival rates and diminished inflammatory 
responses and weight loss, suggest that coprisin analogues could be useful against C. difficile. The 
observation that the coprisin analogue did not prevent inflammation caused by the injection of 
purified toxin A into the ileal lumen suggests that the coprisin anti-inflammatory activity observed 
in vivo is associated with C. difficile growth inhibition rather than with toxin inhibition [68].  
It is worth noting that a genetic locus responsible for resistance to AMPs was identified in 
C. difficile by selecting the CD1352 mutant, which is resistant to nisin [69]. The mutation involves 
the cprK gene, which encodes a histidine kinase regulating a nearby putative ABC transporter 
operon named cprABC. These genes share similar sequences with the lantibiotic immunity systems 
found in lantibiotic-producing bacteria, suggesting that resistance to CAMPs is accomplished 
through the export of the peptides by the ABC transporter. The finding is quite unusual, for at least 
two reasons: i) the mutant strain is resistant to nisin and gallidermin and, to a lesser extent, to 
polymyxin B, whereas typically lantibiotic immunity mechanisms are highly specific for individual 
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peptides; ii) the C. difficile cprABC and cprK genes are not associated with a lantibiotic synthesis 
gene cluster. A homology search for the cprABC operon revealed homologs of these genes in all of 
the other C. difficile isolates sequenced to date, suggesting that this operon encodes a universal 
mechanism of CAMP resistance for the species. Transcriptional analysis of the ABC transporter 
genes revealed that this operon was upregulated in the presence of nisin in wild-type cells and was 
more highly expressed in the CD1352 strain. Results obtained with a cprABC-disrupted mutant 
suggest that other yet unidentified CAMP resistance mechanisms must be present in C. difficile [69]. 
As a whole, these data offer new insights into the complex net of interactions between C. difficile 
and the other bacteria comprising the gut microbiota, namely lantibiotic-producing strains, and open 
unexpected fields of investigation in terms of new targets for therapeutic interventions. 
 
4. Riboswitch and quorum sensing targeting 
4.1 Riboswitch-mediated modulation of gene expression 
Riboswitches, usually located in the 5′ untranslated regions of mRNAs, are RNA sequences that 
include two functionally distinct domains: the aptamer, and the expression platform. Following the 
interaction of the aptamer with a specific ligand, the expression platform undergoes a structural 
change that affects the expression of the adjacent open reading frame (ORF), usually by 
transcription attenuation and/or ribosome binding site (RBS) sequestration [70]. Thanks to the 
complexity of the aptamer, whose secondary and tertiary structure can be compared to that of the 
proteins, the aptamer-ligand interaction is characterized by a high grade of specificity.  
To date, at least 20 distinct classes of riboswitches that recognize small-molecule 
metabolites, divalent cations, or second messengers are reported [71]. Metabolite-sensing 
riboswitches control gene expression in most bacteria, plants, and fungi [72]. In many bacteria 
riboswitches are the receptorial component of a feedback mechanism that regulates the expression 
of genes involved in metabolite biosynthesis or transport. When a metabolite is present at a 
sufficiently high concentration, its binding to the aptamer represses the ORF expression [73].  
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In the past few years, computational virtual screening methods based on information about 
RNA-ligand interactions yielded new RNA binding scaffolds. Since riboswitches evolved as small 
molecule receptors and are present almost exclusively in bacteria, they are considered good targets 
[74]. Indeed, the elucidation of the previously unknown mechanisms of action of some 
antimicrobials such as roseoflavin, pyrithiamine, L-aminoethylcysteine and DL-4-oxalysine, 
showed that these molecules are riboswitch-targeting compounds [74]. The potential of riboswitches 
as drug targets is highlighted by a recent paper from Ster et al., who demonstrate the effectiveness 
of a guanine riboswitch ligand analogue in a model of S. aureus experimental mastitis in cows [75].  
Riboswitches binding the bacterial second messenger cyclic di-guanosyl-5′-monophosphate 
(c-di-GMP) (Fig. 4, 10) control the expression of genes involved in bacterial pathways affecting 
virulence, competence, biofilm formation, and synthesis of flagella. An allosteric ribozyme 
consisting of a c-di-GMP-sensing riboswitch and a group I self-splicing ribozyme was recently 
identified in C. difficile 630 [72]. The proximity of this allosteric ribozyme to the CD3246 ORF 
suggests that the coenzyme-mediated regulation of splicing controls the expression of this gene [70].  
The knowledge of virulence factors involved in C. difficile adaptation to the intestinal 
environment, toxin production, and resistance to antimicrobials is still scarce. Available data 
support the hypothesis that C. difficile production of flagella contributes to pathogenicity [76,77]. 
Observations made by Sudarsan et al. [78] suggest that C. difficile uses a Cd1 riboswitch to regulate 
transcription of the flagellar protein operon to control motility in response to c-di-GMP signalling. 
Moreover, a number of conserved genes encoding proteins involved in the synthesis, degradation, 
or sensing of c-di-GMP were identified in the C. difficile genome. This discovery highlights the 
importance of c-di-GMP signalling in the lifecycle of this pathogen [79]. To determine the functions 
of c-di-GMP in C. difficile, Purcell et al. [76] ectopically expressed an active c-di-GMP synthetase 
or phosphodiesterase to increase or decrease intracellular c-di-GMP, respectively. Results 
demonstrate that in C. difficile 630 intracellular levels of c-di-GMP are inversely related to motility, 
and suggest that relatively small changes in c-di-GMP can alter motility. The recent finding that 
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toxin production is regulated by the flagellar regulon adds complexity to the system and supports 
the importance of further investigation on this issue [80]. Elevated c-di-GMP levels also induced C. 
difficile clumping in vitro, suggesting that C. difficile can form biofilms in the host [76]. These data 
are worthy of further investigation, because nothing is known on C. difficile biofilm formation in 
humans. In a recent paper Ethapa et al. [77] report that biofilm formation by C. difficile has been 
obtained in vitro. These authors found that the process is complex and multifactorial, and suggest 
that it might be a crucial mechanism for clostridial persistence in the host. Other authors, who 
investigated the in vitro biofilm formation by C. difficile, found that bacterial aggregation increases 
when a mixed flora is present [81]. The possibility of a biofilm-like growth that could maintain long-
term colonization in the bowel is suggested by the finding of large aggregates of C. difficile cells, 
described as exaggerated mats, in experimentally infected mice [82]. Biofilm formation could be 
linked to resistance to antibiotics and occurrence of relapses. The ability of c-di-GMP to regulate C. 
difficile motility and aggregation makes this molecule a key player in CDI pathogenesis and a good 
starting point to design riboswitch-targeting drugs. Recently, riboswitches derived from the 
pathogenic bacteria Vibrio cholerae and C. difficile were used to characterize c-di-GMP analogues. 
Early findings support the possibility to design novel compounds that target c-di-GMP riboswitches 
[83].  
 
4.2 Quorum sensing inhibition 
Quorum sensing (QS) is a term used to describe a kind of density-dependent bacterial inter-cellular 
communication based on the constitutive production and secretion of small chemical pheromones 
also defined quorum sensors or autoinducers (AI). When the AI concentration reaches a critical 
detection threshold that depends upon bacterial population density (quorum), the AI interaction with 
species-specific receptors triggers a signal transduction cascade leading to an alteration in gene 
expression. Such multicellular coordination is essential for successful colonization/infection of the 
host by many pathogenic bacteria, because it leads to the expression of virulence factors, or biofilm 
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formation, or both [84]. In Gram-negative bacteria the prototype AI is N-acyl-homoserine lactone 
(AHL) (Fig. 5, 11), typically synthesized by enzymes belonging to the LuxI family, whereas in 
Gram-positive bacteria the AI are often small post-translationally modified peptides. In the late 
1990s a novel autoinducer, AI-2, was identified in Vibrio harveyi cultures, and its production was 
successively detected in a number of both Gram-negative and -positive bacteria [85]. The AI-2 
results from the activity of the luxS gene, whose homologues were identified in about one third of 
the bacterial genomes so far sequenced, including C. difficile [86]. AI-2-containing cell-free 
supernatants from mid-log phase C. difficile upregulated the transcript levels of tcdA, tcdB, and 
tcdE in early-log phase growth C. difficile. However, AI-2 did not significantly increase the 
production of toxin A protein in early-log C. difficile. These results suggest that LuxScd-dependent 
signalling regulates virulence gene expression at the transcriptional level in C. difficile [87]. In their 
study on C. difficile biofilm formation, Ethapa et al. observed that a luxS mutant strain, contrary to 
the biofilm-producer wild type strain, was unable to form even a bacterial monolayer [77]. These 
results strengthen the hypothesis that C. difficile possesses a luxS-mediated QS system, which may 
have a role in biofilm formation.  
In 2004 Kaufmann et al. [88] discovered that an AI produced by Pseudomonas aeruginosa, 
i.e. the N-(3-oxododecanoyl) homoserine lactone (Fig. 5, 12), and its tetramic acid degradation 
product, 3-(1-hydroxydecylidene)-5-(2-hydroxyethyl)pyrrolidine-2,4-dione (Fig. 5, 13), are potent 
antibacterial agents active against a set of Gram-positive bacteria in the ng/ml range. Starting from 
this observation, Ueda et al. [89] investigated the activity of N-(3-oxododecanoyl) homoserine 
lactone and of tetramic acid derivatives against C. difficile. Their results highlight a correlation 
between the antibacterial activity and the length of the acyl side chain of tetramic acid. These 
molecules can be considered potent (effective at 30-50 µM), fast acting (30 min exposure) 
compounds, whose action likely involves membrane destabilization. However, since they are 
inhibited by metal cations, their potential in CDI therapy requires confirmation by experiments 
performed in in vivo CDI models.  
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5. Phage therapy 
5.1 Bacteriophages 
In the 1910s, d’Herelle realized the viral nature of bacteriophages and promoted their use in the 
treatment of bacterial infections [90]. In Russia and Georgia, phage therapy became a common 
treatment for a wide range of infections, and was never abandoned. Phage cocktail preparations, at 
present mainly produced by Microgen, are available at pharmacies as over-the-counter products, 
mostly used for diarrheal diseases and pyogenic infections [91]. In Poland, phage therapy is 
considered an ‘Experimental Treatment’, which can be used when other therapeutic options do not 
exist. In France, made-to-order phage preparations from the Institut Pasteur were used until the 
beginning of the nineties [92]. In other Western countries, phage therapy was declined in the 1940s 
and its development was abandoned after World War II, mainly because of the success and 
availability of antibiotics, but also because of treatment failures due to the poor understanding of 
phage biology and the lack of adequate quality control procedures.  
The global emergence of resistance to antibiotics, and the low number of drugs based on 
new molecular scaffolds currently under development by pharmaceutical firms evoke the spectre of 
a post-antibiotic era [93]. Despite the wide-ranging debate and persistent different opinions, the 
development of phage therapy, together with antibacterial vaccines, immunostimulants, and 
antivirulence therapies is by now considered a high priority approach worthy of research and 
development [94]. The number of papers that support the use of phage therapy reporting controlled 
trials on animals and humans is significant and rapidly increasing [95-104]. Exhaustive reviews of 
the clinical experience with phage therapy at the Eliava institute of Tiblisi (Georgia ) and at the 
Hirszfeld Institute of Wroclaw (Poland) are now available in English [105,107].  
To get an idea of the pros and cons of phage therapy the reader is referred to the up to date 
report by Brüssow [91] on the debates held at recent international conferences on the subject, and to 
[108]. Based on the experience gained in Eastern countries, best results can be achieved by using 
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customized cocktails of phages selected among those able to grow on bacteria isolated from the 
patient. Phage therapy centres in Georgia and Poland keep collections of phages, which are 
constantly updated every six months by selecting mutants that are more active. The quality-
controlled procedure for the production of a bacteriophage cocktail to be used in clinical trials has 
been described in detail [96]. Phage suspensions can be standardized and patented, and can undergo 
the validation process based on preclinical and clinical trials. Custom phage preparations may also 
be developed on request for a single patient, but in this case the product cannot be patented or tested 
before use and it is not compatible with the current licensing rules. In order to make phage therapy 
research and development more attractive to pharmaceutical firms, and to allow its exploitation at 
its best, new regulatory frameworks are needed both in Europe and in the U.S [109,110].  
Today, in Western countries the field of phage therapy for CDI has yet to be explored. To 
our knowledge, only two experimental studies were published on the direct action of lytic 
bacteriophages on C. difficile: the first one, that goes back to 1999, reports on experiments 
performed in a model of hamster infection, whereas in the second one, published in 2010, an in 
vitro batch fermentation model of a C. difficile colonised system was used [111,112]. The results of 
both studies concur to indicate that phages might be an excellent option for CDI treatment and 
prevention.  
Currently, Novolytics Ltd. (Warrington, UK), a company whose mission is to exploit phage 
technology to overcome resistance to antibiotics, is developing topical formulations of a 
bacteriophage cocktail against MRSA, and has a commercial collaboration with a leading UK 
university to design a new phage cocktail targeted at C. difficile [113]. In Bangladesh, Nestlé is 
currently recruiting for a clinical trial to assess safety, tolerability and efficacy of the oral 
administration of T4 phages in young children with diarrhoea due to enterotoxigenic and/or 
enteropathogenic E. coli infections [35]. 
In Western countries, the adoption of phage therapy is thwarted by safety concerns, because 
of the lack of formal and well-controlled large-scale clinical trials. These concerns are mainly 
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related to three aspects: i) bacterial, pyrogen or toxin contamination of phage preparations; ii) the 
possible manifestation of the Herxheimer effect due to the rapid and massive phage-induced 
bacteriolysis; iii) the transfer of bacterial genes encoding virulence factors or antibiotic resistance 
by generalised transduction [110]. These concerns can be overcome, considering that modern 
purification and control techniques make the release of toxic preparations highly unlikely, the 
release of endotoxin can be prevented by appropriate bacteriophage engineering [114], and the 
emergence of phage-resistant strains with increased virulence is an extremely unlikely event.  
On the other hand, phage therapy has properties that in our view make it particularly suitable 
for CDI treatment and prevention: i) the extremely narrow spectrum of action; ii) the lack of 
adverse effects on the host and the possibility to be used in patients allergic to classic antibiotics; 
iii) the fact that a single oral dose may be sufficient; iv) the rapidity of action. Moreover, the lack of 
interference with antibiotics makes phages good candidates for combination therapies, and the oral 
administration removes concerns regarding systemic toxic side effects.  
To achieve the best results with phage therapy, it is mandatory to isolate the causative agent 
of the primary infection and to screen it in vitro against a library of phages to select the most 
effective. The isolation of C. difficile from infected subjects is more difficult than toxin detection, 
but the availability of new culture media that allow bacterial detection in 24 hours with high 
sensitivity is going to facilitate the task [115]. Given the low overall impact on patients, phage 
therapy might be used not only for the therapy of overt CDI, but also for the prevention of CDI 
onset and recurrences.  
 
5.2 Endolysins 
Bacteriophage endolysins (lysins) are two-domain proteins that perform two basic functions: 
substrate recognition and enzymatic hydrolysis of bacterial peptidoglycan. The N-terminal domain 
harbours the enzymatic activity, whilst the cell wall-binding domain located at the C-terminal 
directs the enzyme to its substrate [116]. Lysins were originally developed to control mucous 
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membrane infections, on the assumption that they can lyse Gram-positive bacteria from the outside, 
whereas the outer membrane of Gram-negative bacteria prevents their direct interaction with 
peptidoglycan [117,118]. Lysins have a short half-life (15-20 min), but their action is so rapid that in 
vitro nanogram quantities kill sensitive Gram-positive bacteria in seconds after contact. In vivo 
experiments, performed on a murine model of nasopharyngeal pneumococcal colonization, showed 
that five hours after the local treatment with a purified lysin the number of S. pneumoniae CFU 
recovered from infected animals was reduced to almost undetectable levels [119]. Moreover, lysins 
are per se non-toxic and, unexpectedly, not easily inactivated by antibodies [120]. Since the 
peptidoglycan, which is the lysin target, is not present in eukaryotic cells, it can be expected that 
lysins will be well tolerated by humans.  
The potential of lysins as therapeutic tools against CDI was investigated at the Institute of 
Food Research (Norwich, UK) by researchers of the Mayer group, who identified and characterized 
an endolysin, called CD27L, derived from a C. difficile-infecting bacteriophage [121]. Subsequently, 
a structure-activity analysis of CD27L demonstrated that molecular modifications affect the level of 
activity and/or host range [122]. These results provide a sound basis for further developments, 
considering that the lysin approach may be more attractive to pharmaceutical firms than the whole-
phage approach, in terms of better marketing and patenting opportunities.  
 
6. Probiotics, prebiotics and faecal biotherapy 
6.1 Probiotics 
Probiotics are defined as “live bacteria having a beneficial effect on the host when consumed in 
adequate amounts” [123]. They act by modulating the gut microbiota, by maintaining the integrity of 
the gut barrier, and by modulating the local immune response [124]. These effects are supposed to 
rely on various mechanisms such as bacteriocin production, competition for available nutrients, and 
modulation of the gut cytokine production. Probiotic consumption is considered generally safe, and 
complications rare. A review on probiotic safety evidences that, although cases of bacteremia and 
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endocarditis as well as cases of fungemia (S. boulardii) are described in the literature, there is no 
overall increase in population risk based on usage data [125]. However, a placebo controlled study 
on the effect of a multispecies probiotic including six different strains of freeze-dried, viable 
bacteria (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius, Lactococcus 
lactis, Bifidobacterium bifidum, and Bifidobacterium lactis), administered to severe acute 
pancreatitis patients, showed that mortality in the probiotic-treated group was about twice as high as 
in the placebo group, with a higher incidence of mesenteric ischemia [126]. Although to date this is 
the only trial to infer such a relationship, it is enough to suggest that probiotics should be avoided in 
critically ill patients. A recent study commissioned by the U.S. Agency for Healthcare Research and 
Quality reiterates the apparent safety of probiotics when used to prevent or treat diseases but 
acknowledges limited safety reporting of existing studies. Accordingly, a recent position paper 
issued by the U.S. FDA clarifies that its limited oversight of probiotics as a “food” applies only to 
the ingestion of these agents by healthy individuals to maintain gastrointestinal health. This 
document also asserts that the use of probiotics to prevent, treat, or mitigate disease would classify 
these agents as “drugs” and would require the same stringent approval process as any 
pharmaceutical product or device [127]. Probiotics are not recommended for CDI in the 2010 
SHEA/IDSA treatment guidelines. [128] However, a placebo-controlled clinical trial assessed the 
efficacy of Lactobacillus acidophilus + L. casei capsules in the prophylaxis of both antibiotic-
associated diarrhoea and C. difficile-associated diarrhoea [129].  
Several bacterial and fungal species were studied or are currently under study to determine 
their efficacy against CDI either as single probiotic agents or in combination with other agents. 
These agents include Saccharomyces boulardii and several Lactobacillus, Clostridium, 
Streptococcus, and Bifidobacterium species. S. boulardii and Lactobacillus rhamnosus GG are two 
of the best characterized probiotic organisms for use in CDI. A meta-analysis of the efficacy of S. 
boulardii performed in 2010 points out that this yeast may have a favourable impact on CDI 
prevention, based on the following evidence: i) it produces a serine protease that directly degrades 
 23
C. difficile toxins; ii) it destroys the colonic receptor site for C. difficile; iii) it upmodulates the 
immune response to toxin A and B. Furthermore, the treatment with S. boulardii was effective in 
several experimental models of CDI in hamsters, gnotobiotic mice, rats, and turkeys [130]. However, 
the usefulness of S. boulardii in CDI is still debated. In a review of the available literature published 
in 2009, Miller concluded that probiotics, S. boulardii included, do not have a role in CDI 
prevention or therapy [132]. However, since 1989, sporadic human cases or small case series reports 
concur to the view that S. boulardii shows promise for CDI prevention, and a recent paper by 
Johnson et al. suggests that the primary prevention of CDI with probiotics may be achievable [131]. 
In conclusion, most authors state that more clinical trials of sufficient size and with rigorous design 
are needed to confirm these findings and to develop consistent treatment protocols.  
In 2011, Cartman advocated the development of new generation of probiotics based on 
Clostridium species [133]. In fact, since 1985 it is known that intestinal colonization with a 
nontoxigenic C. difficile strain protects hamsters against a challenge with toxigenic C. difficile [134]. 
Similar experiments performed in 2009 in the hamster model showed that colonisation by non-
toxigenic C. difficile during antibiotic administration is an effective prevention strategy against 
infection with toxigenic strains [135].  
The mechanism by which nontoxigenic strains prevent colonization by toxigenic C. difficile strains 
has not been elucidated, but the use of nontoxigenic C. difficile spores to prevent primary or 
recurrent CDI is an attractive strategy [136].  
 
In a controlled study, the co-administration of spores of Clostridium butyricum MIYAIRI, 
commonly sold in Japan as tablets for balancing the intestinal flora, significantly reduced the 
incidence of antibiotic-associated diarrhoea in children [137]. Recently, ViroPharma Inc. (Exton, 
PA, USA) completed a phase I clinical trial showing that the administration of an oral suspension of 
spores of the nontoxigenic C. difficile strain M3 (VP20621) is well tolerated and effectively induces 
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the colonization of the gastrointestinal tract of subjects pretreated with vancomycin [138]. The 
preparation is now scheduled for a phase II trial. 
 
6.2 Prebiotics 
Since the late 1990s, the word prebiotic has been used to indicate “dietary substances that by 
inducing specific changes in the composition and/or activity of the gastrointestinal microbiota 
confer benefits upon host health” [139]. Today, prebiotics are considered potentially useful tools to 
manipulate the microbiota composition. Non-digestible oligosaccharides like the chicory fructans 
reach the caecum without undergoing structural changes, but they are not found in the stools, being 
metabolized by the colonic flora. Their ability to increase the number of bifidobacteria and lower 
the intraluminal pH interferes with the engraftment of incoming pathogenic germs. In addition to 
this properly demonstrated effect, other less evident functions of prebiotics affect the bioavailability 
of minerals and the metabolism of lipids, resulting in potential subtle benefits on a variety of 
pathological conditions including intestinal infections, cardiovascular disease, type II diabetes, 
obesity, osteoporosis and cancer [140,141]. A study performed on normal and antibiotic-treated 
faecal microbiotas in vitro showed that the addition of nondigestible oligosaccharides enhanced 
resistance against C. difficile colonization in antibiotic-free, but not in clindamycin-treated cultures 
[142]. In a randomized study on 72 infants, the administration of fructo-oligosaccharides had no 
significant impact on intestinal flora and C. difficile counts or toxin detection in faeces [143]. These 
results indicate that the research in this field is still at a very basic level. 
 
6.3 Faecal biotherapy 
The rationale of faecal biotherapy, or faecal transplantation (FT), relies on the observation that 
normal colonic flora controls C. difficile overgrowth. The transplant of the entire faecal ecosystem 
obtained from a healthy donor is highly effective, achieving 73-100% clinical resolution rates in 
recurrent or refractory CDI 140,141 [144,145]. The transplant can be delivered by nasogastric tube, 
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colonoscopy or retention enema. The last methodology is the less expensive and the less likely to 
cause injuries to patients [146]. Given the by now widely recognized effectiveness of FT, the major 
concerns on its use relate to the possible transfer of pathogens, especially viruses. Indeed, the donor 
screening is perhaps the most expensive part of the procedure. This problem could be overcome by 
the collection of multiple donations, which could be stored frozen, from a small number of 
thoroughly screened donors. The feasibility of this kind of procedure is supported by a recent paper 
by Jorup-Rönström et al. [147]. 
The main possible evolution of faecal transplant consists in bacteriotherapy, i. e. a treatment 
based on defined bacterial cocktails able to restore the physiological microbiota and to displace C. 
difficile from the gut. In 1989, Tvede and RaskMadsen reported that a mixture of ten different 
facultative aerobic and anaerobic bacteria was able to resolve C. difficile infection in a small 
number of human patients [148]. Perhaps the importance of this finding was not fully appreciated at 
the time, and there were no further developments. However, recently Lawley et al., working with a 
CDI mouse model, demonstrated the effectiveness of MixB, a mixture of six intestinal bacteria 
including three previously described species, Staphylococcus warneri, Enterococcus hirae, 
Lactobacillus reuteri, and three novel species, Anaerostipes sp. nov., Bacteroidetes sp. nov. and 
Enterorhabdus sp. nov., in the resolution of intestinal disease and contagiousness [149]. The 
protocol that was used to identify the six active bacterial species is rather complex and can be 
performed more easily in an animal model, but this work lays the conceptual and practical 
foundations for the development of bacteriotherapy. This approach overcomes the concerns about 
the psychological impact on patients, and is more attractive to the pharma industry, because 
bacterial cocktails could be patented. 
 
7. Toxin inhibition 
In principle, virulence factor targeting has the double advantage of avoiding the selection of 
resistant strains and the disruption of normal microbiota. The pathogenic effect of C. difficile is 
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mediated by toxins A and B, that share 45% sequence similarity and have four conserved regions: 
an N-terminal enzymatic region, a protease domain, a C-terminal receptor-binding region, and a 
translocation region. Following endocytosis by the cells of the intestinal mucosa, the toxins undergo 
a complex process in which the autocatalytic activity of the protease domain releases the enzymatic 
N-terminal region into the cytosol. This enzyme irreversibly glucosylates the RhoA family of small 
GTPases inducing cell apoptosis [150].  
Various strategies have been explored to achieve intraluminal neutralization of C. difficile 
toxins, mainly by using antibodies or binding agents. For an exhaustive review of this issue, the 
reader is referred to [136]. Passive immunity with intravenous monoclonal antibodies targeting both 
toxins seem a promising approach [ 151 Gerding 2012]. In fact, in a phase II clinical trial the 
administration of monoclonal antibodies against C. difficile toxin A and B by i.v. infusion 
significantly reduced the rate of recurrences [152]. The active immunity option is also being actively 
investigated, and phase I trials demonstrated the antigenicity of toxoid-based vaccines [153].  
Toxin-binding agents such as cholestyramine and colestipol or tolevamer showed poor 
efficacy both in in vitro models of human gut and in phase III clinical trials [154]. A different 
approach involves the identification of molecules able to selectively inhibit the enzymatic activities 
of the two toxins, i.e. the autocatalytic protease and the cytotoxic effector domain [155]. In this field, 
the identification of inhibitors of the cysteine protease of the B toxin [155] is a promising starting 
point, which support the validity of the approach and is worthy of further development. A problem 
that could arise with this category of drugs is that almost all of the protease inhibitors currently 
approved for anti-HIV therapy cause diarrhoea and hyperlipidemia [156]. Whereas hyperlipidemia 
may be a small concern, due to the short duration of CDI therapy, drug-induced diarrhoea could 
exacerbate the symptoms of the patients. Therefore, this problem should be taken into account in 
the development of protease inhibitors.  
 
8. Expert opinion 
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The strategies to solve the CDI problem must cope with the multiple challenges posed by the 
bacterium. Since C. difficile is commonly found in wild and domestic animals, its spores are 
destined to remain in the environment indefinitely, and the eradication of the species is not feasible. 
Toxoid-based vaccines are being developed, and some of them are in phase I clinical trials [35]. One 
problem of strategy based on vaccines is to define the pre-emptive or therapeutic use of the vaccine, 
and the choice of subjects that should be vaccinated, considering that CDI has an incidence of 20-
30/100,000 in Western countries. The focused, therapeutic administration of anti-toxin monoclonal 
antibodies, currently in phase II clinical trials, would probably be less expensive.  
CDI onset could be prevented by the development and proper use of narrow-spectrum 
antibiotics, which should substitute the broad-spectrum drugs currently in use for common 
infections. However, huge advances in this field are unlikely, mainly because of low marketing 
opportunities. Specific anti-C. difficile narrow-spectrum antibiotics based on new molecular 
scaffolds and non inferior to fidaxomicin are being developed. In the next future, they should be 
able to lower the rate of recurrences and to overcome the problem of resistance,which by now is 
sporadically occurring against vancomycin and metronidazole.  
More ambitious strategies aim to replace antibacterials with virulence-targeting factors. The 
research on molecules that target riboswitches and QS is still at a very basic level, whereas the field 
of AMPs is rapidly developing and bacteriocin research could profitably merge with probiotic 
optimization studies. Probiotics can be added as adjuvants to antibiotic therapy, but after more than 
ten years of use their utility is still debated.  
In our view, phage therapy constitutes a tool that is worthy of a second chance in Western 
countries. It has the advantage of short term availability and does not require huge investments, 
thanks to the wide experience gained in France and in the East Europe countries. The isolation of 
lytic phages targeting C. difficile should not be a problem, considering that recently virulent phages 
against C. perfringens were easily isolated and characterized [157]. The association of phage therapy 
with antibiotics gives synergic results, but the ultimate goal should be to use antibiotics as the last 
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option, instead of the first, with positive outcomes on the resistance problem. For phage therapy to 
work at its best, the ideal clinical setting would include the possibility to rapidly identify and match 
the infecting bacterium to large phage bank databases. In order to achieve this result, the 
interdisciplinary cooperation of bioinformaticists, health care professionals, and phage researchers 
is needed [158]. The adoption of this approach in Western countries would require the modification 
of some regulatory guidelines in Western Europe and in the U.S., and, equally important, a change 
in the way of thinking of physicians and health policy decision-makers. This should involve a shift 
from the standard-oriented therapeutic approach towards a more personalized medicine in which 
specific products (i.e. phages or phage cocktails) are specially prepared for the treatment of an 
individual patient. Whereas the medical and scientific community is becoming aware of the 
problem of antibiotic resistance, in Western countries the knowledge of the possibilities of phage 
therapy is rather poor.  
The situation, which in some respects resembles the difficulties that hindered the 
introduction of the first vaccines, is appropriately illustrated by a recent event: in 2011, Germany 
experienced the largest epidemic ever recorded due to Shiga toxin-producing E. coli. The genome 
sequences of the pathogen revealed a food-borne clonal outbreak due to the enteroaggregative E. 
coli O104:H4 strain. In these infections, the administration of antibiotics is counter-indicated 
because they can activate toxin expression. In addition, the epidemic strain was highly resistant to 
antibiotics, which left few options beyond supportive therapy. A total of 3,842 cases were reported, 
with 18 deaths due to E. coli gastroenteritis and 35 deaths due to haemolytic uremic syndrome [159]. 
Phages and phage cocktails targeting the O104:H4 strain were available at the Nestlé Research 
Center (NRC, Lausanne, Switzerland), at the Pasteur Institute in Paris and at the Eliava Institute 
(Tiblisi, Georgia). Neither the medical community nor the public health authorities inquired about 
or asked for these phages during the outbreak, that lasted about two months, and the offer of phages 
by NRC was not considered by the German public health sector [91]. We can attribute this kind of 
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reaction to the poor knowledge about phage therapy in the West, and assume that in Russia, in 
Poland or in France the emergency would have been handled with a different approach.  
Severe refractory CDI and repeated recurrences could benefit from toxin neutralization, a 
possibility that needs further investigation. The best and already available option for the treatment 
of these often severe and otherwise hopeless conditions is FT. Despite the difficulties of 
psychological order, for now FT remains the most successful treatment for recurrences. It is 
technically less challenging and less risky than blood transfusion, and there are no major obstacles 
to its adoption.  
Finally, we must say that both phage therapy and FT are therapeutic procedures inherently 
not suitable for patenting: as such, they do not attract investments for development and refining, and 
their implementation requires the commitment of publicly-funded institutions, national reference 
centres and hospital laboratories.  
 
Article highlights 
• Infectivologists are facing a world-wide increase of antibiotic-associated severe C. difficile 
enteric infections, whose management is currently far from satisfactory. 
• New antibiotic-like molecules or antimicrobial peptides like thuricin CD, which has a very 
narrow spectrum of action and can selectively target C. difficile without disrupting the 
normal gut microbiota, are under development. 
• More ambitious and long-term alternative strategies involve the development of non-
antimicrobial molecules targeting the expression of virulence factors by acting on 
riboswitches or quorum sensing. 
• Phage therapy could be an excellent alternative to antibiotics for both CDI prevention and 
treatment. It deserves a second chance in Western countries, where it is little known.  
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• Probiotic co-administration with antimicrobials may limit the incidence of CDI. However, 
their usefulness is still debated and they are not validated for the treatment of established 
CDI. The development of non-toxigenic C. difficile strains looks promising. 
• Faecal therapy is emerging as the most successful treatment for severe refractory CDI and 
relapses. Standardized mixtures of faecal bacteria able to reconstitute the normal intestinal 
microbiota are under development. 
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Figure legends 
Fig. 1. Chemical structures of drugs approved for CDI. 
Fig. 2. Chemical structures of antibacterial molecules active against C. difficile currently under 
development. 
Fig. 3. Chemical structures of antibacterial molecules active against C. difficile currently under 
development. 
Fig. 4. Chemical structure of the riboswitch ligand cyclic di-guanosyl-5′-monophosphate. 
Fig. 5. Chemical structures of QS inhibitors. 
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